New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
05:05 EDTBAYRY, ONXXBayer, Onyx announce Phase 3 DECISION trial of Nexavar meets primary endpoint
Bayer HealthCare Pharmaceuticals (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that a Phase 3 trial of Nexavar tablets in patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. Adverse events were generally consistent with the known profile for Nexavar. Data from this study are expected to be presented at an upcoming medical meeting.
News For BAYRY;ONXX From The Last 14 Days
Check below for free stories on BAYRY;ONXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
September 16, 2014
07:31 EDTBAYRYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 8, 2014
07:15 EDTBAYRYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use